NCT03050905 - Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2017

Primary Completion Date

November 16, 2017

Study Completion Date

November 28, 2018

Conditions

HCV Coinfection

Interventions

DRUG

VEKIRAX

"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"

DRUG

EXVIERA

"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"

Trial Locations (1)

Unknown

Haemek medical center, Afula